 | | Vol. 12.19 – 28 May, 2021 |
| |
|
|
| Researchers showed that up-regulation of hexose-6-phosphate dehydrogenase protein occurred in prostate cancer tissues of men treated with enzalutamide, human-derived cell lines, and patient-derived prostate tissues treated ex vivo with enzalutamide.
[Science Advances] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists evaluated the efficacy and explored the mode-of-action of the PSMA-TTC BAY 2315497, an antibody-based targeted alpha therapy, in combination with the androgen receptor inhibitor darolutamide.
[Clinical Cancer Research] |
|
|
|
| Oral administration of an antibiotic mixture in prostate cancer (PCa)-bearing mice fed a high-fat diet containing a large proportion of lard drastically altered the composition of the gut microbiota including Rikenellaceae and Clostridiales, inhibited PCa cell proliferation, and reduced prostate Igf1 expression and circulating IGF-1 levels.
[Cancer Research] |
|
|
|
| The authors investigated the biological function and molecular mechanism of the nuclear receptor peroxisome proliferator-activated receptor-gamma 2 (PPARG2) in prostate cancer.
[Cell Death & Disease] |
|
|
|
| Researchers developed a rapid and immune-sufficient mouse model for liver metastasis of prostate cancer via orthotopic injection of organoids from PbCre+; rb1f/f;p53f/f mice.
[Cell Proliferation] |
|
|
|
| Scientists investigated whether chronic intestinal inflammation led to pro-inflammatory changes associated with tumorigenesis in the prostate.
[Prostate Cancer and Prostatic Diseases] |
|
|
|
| Investigators observed and investigated the mechanism of induction of SLCO1B3 by abiraterone. Prostate cancer cells were treated with anti-androgens and assessed for SLCO1B3 expression by qPCR analysis.
[Scientific Reports] |
|
|
|
| MiR-9-5p reduced NUMB expression and inhibited numerous prostate cancer stem cell properties including proliferation, migration, invasion as well as self-renewal.
[Scientific Reports] |
|
|
|
| To develop an enzalutamide-resistant cell model for molecular mechanism investigation of enzalutamide-resistance, researchers continuously treated C4-2B cells with multiplied concentrations of enzalutamide.
[Experimental Biology and Medicine] |
|
|
|
|
| Investigators discuss progress made in the design of T- and NK cell immune engagers in addition to chimeric antigen receptor products specifically designed for prostate cancer that are currently under investigation in clinical trials.
[Prostate Cancer and Prostatic Diseases] |
|
|
|
|
| Prostate Cancer Foundation has announced its new $2.5 million commitment to launch the Drew Foundation Precision Oncology Center of Excellence in collaboration with the University of California, San Francisco, and the San Francisco VA Health Care System to deliver best-in-class precision oncology treatments to Veterans with prostate cancer.
[Prostate Cancer Foundatio] |
|
|
|
| Foresee Pharmaceuticals Co., Ltd. announced that the FDA has approved the New Drug Application for CAMCEVI® 42 mg, a ready-to-use six-month subcutaneous depot formulation of leuprolide mesylate, as a treatment of advanced prostate cancer.
[Foresee Pharmaceuticals Co., Ltd.] |
|
|
|
|
| November 17 – 19, 2021
Virtual |
|
|
|
|
|
| | Cedars-Sinai Medical Center – Los Angeles, California, United States |
|
|
|
| | H. Lee Moffitt Cancer Center – Tampa, Florida, United States |
|
|
|
| | The University of Edinburgh – Edinburgh, Scotland, United Kingdom |
|
|
|
| | Cleveland Clinic – Cleveland, Ohio, United States |
|
|
|
| | Peter MacCallum Cancer Centre – Victoria, Australia |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
